In-Licensing Opportunity Assessment in a Subsegment of Anticoagulant Agents for the EU-5 Market

Publications
Category:
Published on:
May 2, 2020
Written by:
Joris Pezzini

When our client, a renowned European pharma company, was interested in an in-licensing opportunity to drive its future growth while achieving significant commercial synergies, Alira Health performed a thorough analysis to understand the sales potential and value.

Read on to see how Alira Health’s in-depth analysis helped our client move forward with confidence.

For more information or for a PDF of this infographic, contact Joris Pezzini.

To know more about Alira Health Management Consulting services

Click here

Related news

News September 6, 2022
Alira Health Expands North American Capabilities with the Acquisition of Artisan Healthcare Consulting
The acquisition of Artisan strengthens and extends Alira Health’s Market Access and Management Consulting advisory practices in North America and globally.
Biotech Market Access Pharma Therapeutics
Publications August 25, 2022
Why—and When—to Use a CDMO
Pharmaceutical development companies of all sizes frequently outsource their Active Pharmaceutical Ingredient (API) manufacturing to CDMOs for various reasons. In this article, we explore(...)
CDMO Pharma Research and Development
Publications June 23, 2022
Developing Data Specialist Talent: Collaboration Is Key
Companies across Pharma and MedTech need talented people to cover the range of data-related challenges. Discover what this means for developing talent throughout the industry.
Data Specialist MedTech Pharma
News May 11, 2022
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
MedTech Patient Engagement Pharma
News April 5, 2022
Alira Health Strengthens Clinical Operations with the Acquisition of Sourcia
We acquired a full-service Contract Research Organization (CRO), Sourcia, that provides services for Phase I to Phase IV clinical trials with a focus on biotech, medical devices, and(...)
Clinical MedTech Patient Engagement Pharma Regulatory Research & Development
Publications March 31, 2022
The FDA’s Project Orbis Can Speed up the Delivery of Your New Oncology Drug to Global Markets
Are you developing an oncology drug? Project Orbis, a program coordinated by the U.S. Food and Drug Administration (FDA), allows you to register your product in several countries with(...)
Pharma Regulatory
Events March 4, 2022
Bio Europe Spring 2022
Meet us at Bio Europe Spring 2022. Connect with us to learn how Alira Health can help accelerate innovation and deliver tomorrow’s standard of care.
Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.